期刊文献+

雷帕霉素对急性髓系白血病细胞系HL-60和HL-60/VCR生长的抑制作用

Effect of Rapamycin on Proliferation of Acute Myeloid Leukemia Cell Lines HL-60 and HL-60/VCR
下载PDF
导出
摘要 为了探讨mTOR抑制剂雷帕霉素对急性髓系白血病(acute myeloid leukemia;AML)细胞的增殖和药物敏感性的影响。以AML细胞株HL-60和多药耐药HL-60/VCR细胞系为研究对象,采用MTT法测定生长曲线和流式细胞术检测细胞周期;Western blot检测P糖蛋白(P-glycoprotein,Pgp)的表达。结果显示:与空白对照组细胞比较,雷帕霉素能抑制HL-60和HL-60/VCR细胞生长增殖(p<0.05),且随着浓度升高,增殖抑制率逐渐增高,24-72小时的细胞增殖抑制率随着时间的延长而有所增高(p<0.05),同时可阻滞细胞从G1期到S期的细胞周期转换。雷帕霉素抑制HL-60/VCR细胞的Pgp蛋白的表达。与柔红霉素单独应用相比,雷帕霉素50nmol/L、100nmol/L与柔红霉素联合应用使HL-60和HL-60/VCR细胞增殖抑制率明显增高(p<0.05),尤其是当先加雷帕霉素,而24小时后再加柔红霉素时。结论:mTOR抑制剂雷帕霉素对HL-60和多药耐药的HL-60/VCR细胞的生长均有抑制作用,除伴G0/G1期阻滞外,还增加细胞对柔红霉素的敏感性,这为临床难治性AML治疗提供新的治疗手段。 In order to investigate the effect of rapamycin on the proliferation of human acute myeloid leukemia (AML) cells,the sensitive cells HL-60 and multidrug-resistant HL-60/VCR cells were chosen as research objects. The proliferation of cells was detected by growth curve method. The flow cytometer was used to analyze cell cycle. The expression of P-glycoprotein (Pgp) was determined by Western blot. The results demonstrated that there was a significant difference of cell growth inhibition rate between control group and rapamycin group (p0.05). The cell growth inhibition rate was dose- and time- dependent(p0.05). Flow cytometry detection showed that the cell percentage of G1 phase in rapamycin group was higher than that in group without rapamycin,and that of S phase was lower. The cell growth inhibition rate in 50 nmol/L and 100 nmol/L rapamycin plus daunorubicin (DNR) group was more than that in DNR alone group(p0.05),especially when DNR was added at 24 hours interval after RAP. The expression of Pgp of HL-60/VCR cells was inhibited by rapamycin. It is concluded that the rapamycin can inhibit the proliferation of sensitive HL-60 and multidrug resistant HL-60/VCR cells. It can also increase sensitivity of HL-60 and HL-60/VCR cells to DNR,which provides new strategy for the therapy of refractory AML.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第6期1464-1468,共5页 Journal of Experimental Hematology
关键词 急性髓系白血病 雷帕霉素 HL-60细胞 HL-60/VCR细胞 acute myeloid leukemia rapamycin HL-60 cell HL-60/VCR cell
  • 相关文献

参考文献10

  • 1Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol, 2009;145 (5) :569 -580.
  • 2Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol, 2009 ; 27 ( 2 ) :45 - 47.
  • 3Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005 ; 105 ( 6 ) : 2527 - 2534.
  • 4张丽红,林凤茹.雷帕霉素对白血病细胞株的影响[J].中国实验血液学杂志,2009,17(4):870-873. 被引量:1
  • 5Bohm A, Aichberger KJ, Mayerhofer M, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest, 2009 ;39 (5) :395 - 405.
  • 6Boehm A, Mayerhofer M, Herndlhofer S, et al. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemo- therapy-refractory AML. Eur J Intern Med, 2009 ; 20 ( 8 ) : 775 - 778.
  • 7Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets, 2009 ; 13 ( 10 ) : 1193 - 1203.
  • 8Janus A, Linke A, Cebula B, et al. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs, 2009 ;20 ( 8 ) :693 - 701.
  • 9Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res, 2009 ; 15 (21) :6732 - 6739.
  • 10Martelli AM, Evangelisti C, Chiarini F, et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs, 2009 ; 18 (9) : 1333 - 1349.

二级参考文献6

  • 1Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood,2006 ; 107:2223 - 2233.
  • 2Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005 ; 105 : 2527 - 2534.
  • 3Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA, 2001 ;98:10314 - 10319.
  • 4Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell, 2002 ; 1:417 - 420.
  • 5Yin B, Morgan K, Hasz DE, et al. Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia, 2006 ;20 : 151 - 154.
  • 6Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AMI cells. Blood ,2005 ;106:4261 - 4268.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部